In Brief: AccuMed/Olympus
This article was originally published in The Gray Sheet
AccuMed/Olympus: AccuMed ships the first 25 AcCell 2000 and 2001 automated cytopathology systems to Olympus, fulfilling initial shipment requirements under a recent distribution agreement. The agreement gives Olympus exclusive rights in the Western Hemisphere to distribute AccuMed's AcCell workstations, which are used in screening Pap smear and other cell samples. The deal also includes rights to the yet-to-be-approved AccuMap system, which employs software to "map and automatically focus the cell specimen prior to human screening," AccuMed says. AccuMed plans to begin training Olympus' technical and quality personnel during the week of July 8. In cooperation with Olympus, AccuMed can continue to promote the system in the Americas...
You may also be interested in...
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.